2021-11-17T03:29:32-00:00 2020-12-31 KPMG LLP 1918 8th Avenue Suite 2900 Seattle WA 98101 990 2020-01-01 910653422 Benaroya Research Institute at Virginia Mason BENA 2063426500 1201 Ninth Avenue Seattle WA 98101 Michael Labosier Chief Financial Officer 2021-11-17 true Michael Labosier 999009999 Sue Robison P00560072 2069134000 2021-11-01 2 AAL1 IAL1 2020 2022-09-23 18:48:47Z Jane Buckner MD 1201 Ninth Avenue Seattle WA 981012795 67924339 false X http://www.benaroyaresearch.org X 1956 WA To advance the science that will predict, prevent, reverse, and cure diseases of the immune system. 22 17 339 3 0 62867601 60644155 9656398 6105766 322628 465981 432312 517857 73278939 67733759 23652782 24013128 0 29080641 30263381 0 0 18713253 17073013 71446676 71349522 1832263 -3615763 95747100 100142600 45073162 49711912 50673938 50430688 X Advancing the science that will predict, prevent, reverse, and cure diseases of the immune system such as autoimmune disease, allergy, and asthma. false false 35789088 22146468 Interventional Immunology - Includes Immune Tolerance Network Program. See Schedule O. 12495092 302067 Translational Immunology. See Schedule O. 9926163 1564593 Fundamental Immunology. See Schedule O. 907893 6105766 59118236 true true false true false false false false false true true true false false true false true false false false true true false false false false false true false true true false false true false false false false false false false false false false false false true false false false false true 66 0 true 339 true false false false false false false false false false false false false X 22 17 false false true false true true true true true false false true true true true true true true true false WA X Michael Labosier CFO 2063426505 1201 Ninth Avenue Seattle WA 98101 Gary Kaplan MD Director 001.00 054.00 X 0 1831863 86010 David Aboulafia MD Director 001.00 050.00 X 0 590841 53545 Jane Buckner MD Ex Officio, President 040.00 X X 542122 0 27200 Joyce Lammert MD PhD Director 001.00 050.00 X 0 326956 31798 Margaret McCormick PhD Executive Director Chief Operating Officer 040.00 X 308440 0 31600 William Kowk PhD Research Member 040.00 X 251185 0 29600 Steven Ziegler PhD Director of Academic Affairs 040.00 X 241678 0 23532 Carla Greenbaum Director 040.00 X 231145 0 32562 Michael Labosier Chief Financial Officer 040.00 X 200783 0 32612 Bolong Cao Business Development Director, Business Development 040.00 X 192045 0 30474 Daniel Campbell PhD Center Director of Discovery Science 040.00 X 201917 0 18764 Philip Bernstein Research Member 040.00 X 192321 0 25972 Gerald Nepom MD PhD Program Director, ITN 040.00 X 164068 0 27444 Catherine Zimmerman Director 001.00 X 0 0 0 Jeffrey S Wortley Director, Treasurer 001.00 X X 0 0 0 Christopher Wilson MD Director 001.00 X 0 0 0 David Williams Director 001.00 X 0 0 0 Diane St John Director, Secretary 001.00 X X 0 0 0 Nabil Istafanous Director 001.00 X 0 0 0 Paul Hughes Director 001.00 X 0 0 0 Frank Dvorak PhD Director, Vice-Chair 001.00 X X 0 0 0 Carla DewBerry Director 001.00 X 0 0 0 Tom Cohen Director, Chair 001.00 X X 0 0 0 Ben Reiber Director 001.00 X 0 0 0 Kirk Nelson Director 001.00 X 0 0 0 Robert Williams Director 001.00 X 0 0 0 Claire Bonilla Director 001.00 X 0 0 0 Brian Kotzin Director 001.00 X 0 0 0 Proctor Schenk Director 001.00 X 0 0 0 Erin Talbott Director 001.00 X 0 0 0 2525704 2749660 451113 64 false true false KPMG LLP 1918 Eighth Ave Suite 2900 Seattle WA 98101 Auditing Consulting 185955 Genesis Lighting 4514 S 256th Street Kent WA 980326517 Electrical contractor 123180 Finley & Cook 601 N Broadway Shawnee OK 74802 Software Support 108585 3 500000 47909509 12234646 60644155 Commercial Studies 621500 5569393 5569393 Core Services and Other 621500 536373 536373 6105766 465981 465981 708437 190580 517857 517857 517857 67733759 6105766 983838 21708319 21708319 0 2304809 2304809 0 1471746 650421 821325 0 21839656 15830174 6009482 1899074 1326305 572769 3376335 2358018 1018317 1676570 1170909 505661 0 52947 52947 117455 117455 0 0 2083594 1541545 542049 71896 -544 72440 86986 26786 60200 1716589 928447 788142 0 3229424 2635608 593816 64287 49657 14630 0 46224 33876 12348 793841 690642 103199 0 3244259 2661744 582515 161954 106848 55106 Supplies and Miscellaneous Expenses 3817656 3697861 119795 Other Purchased Services 244917 137084 107833 Patient Costs 927121 927121 Research Participants Expenses 184285 184285 229578 148321 81257 71349522 59118236 12231286 0 5968573 4851464 1346562 3056613 13407687 15695207 2190375 3661757 642728 422636 80343115 54590867 23690426 25752248 12334516 9469982 33053950 33972375 3112283 3260318 95747100 100142600 10369555 11286354 6925668 7768042 25037716 28256552 2740223 2400964 45073162 49711912 X 17545065 16020806 33128873 34409882 50673938 50430688 95747100 100142600 -3615763 3372513 X false true X true true true X Virginia Mason Medical Center Seattle WA 71346495 60243416 59023034 62867601 60664155 314144701 71346495 60243416 59023034 62867601 60664155 314144701 28272944 285871757 933027 994910 729749 945520 1174418 4777624 8553010 6781431 8229643 9656398 6105766 39326248 358248573 39326248 0.79200 X Part II Section B Line 10 2020 Other Income of 6,105,766 is comprised of 5,569,393 of Clinical Research Program revenue, 430,308 of External Core income, and 106,065 of miscellaneous income. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED X 129023 80424 209447 71349522 1232542070 71349522 1232751517 1000000 1000000 250000 250000 false 1000000 1000000 1000000 1000000 4000000 6000000 284247 294038 307100 209447 1094832 250000 250000 250000 250000 1000000 1500000 175480 180464 183519 129023 668486 false false false false false false false false false false false II-A A Benaroya Research Institute at Virginia Mason, EIN 91-0653422, 1201 Ninth Avenue, Seattle, WA 98101. Non-electing member. 0 Lobbying Expenditures. Excess Lobbying Expenditures 0. II-A A continued Virginia Mason Medical Center, EIN 91-0565539, 1100 Ninth Avenue, Seattle, WA 98101. Electing member. Grassroots Lobbying Expenditures 129,023 Direct Lobbying Expenditures 80,424. Excess Lobbying Expenditures 0. Tax year ending December 31, 1998 was the first year in which Virginia Mason Medical Center made the election under Section 501h. The election was not revoked before the start of the tax year ending December 31, 2020. II-A A continued Virginia Mason Health System, EIN 91-1351110, 1100 Ninth Avenue, Seattle, WA 98101. Non-electing member. 0 Lobbying Expenditures. Excess Lobbying Expenditures 0 II-A A continued Virginia Mason Institute, EIN 26-3763656, 1100 Ninth Avenue, Seattle, WA 98101. Non-electing member. 0 Lobbying Expenditures, 0 Excess Lobbying Expenditures. false false true true 756906 756906 52355544 32903351 19452193 215595 201545 14050 24787821 21485971 3301850 2227249 2227249 25752248 Financial derivatives and other financial products Closely-held equity interests Interest in Net Assets of Virginia Mason Health System 33972375 F 33972375 Federal income taxes Lease liability Relates to Right-of-Use Asset 2400964 2400964 71106272 3372513 3372513 67733759 67733759 71349522 71349522 71349522 X 1 In accordance with ASC topic 842 Leases, the Research Institute adopted the new standard and recorded lease liabilities over lease terms between 3 and 10 years. The leases are primarily for real estate, including off-campus outpatient facilities, medical office buildings, and corporate and administrative offices. true Europe Including Iceland and Greenland Conferences Medical Research 1720 East Asia and the Pacific Conferences Medical Research 1008 North America Conferences Medical Research 556 Europe Including Iceland and Greenland Grant Medical Research 1881083 East Asia and the Pacific Grant Medical Research 423727 2308094 2308094 Europe Including Iceland and Greenland Medical Research 185102 Wire Transfer Europe Including Iceland and Greenland Medical Research 6000 Wire Transfer Europe Including Iceland and Greenland Medical Research 762187 Wire Transfer Europe Including Iceland and Greenland Medical Research 706340 Wire Transfer Europe Including Iceland and Greenland Medical Research 33724 Wire Transfer Europe Including Iceland and Greenland Medical Research 187730 Wire Transfer East Asia and the Pacific Medical Research 2473 Wire Transfer East Asia and the Pacific Medical Research 370768 Wire Transfer East Asia and the Pacific Medical Research 5057 Wire Transfer East Asia and the Pacific Medical Research 45429 Wire Transfer 10 false false false false false false Part I Line 2 Sub-recipient Monitoring Policy - medical research sub awards - BRI has formal policies and procedures to assure full compliance with applicable policies and laws governing federal grants. The Sub-recipient Monitoring Policy provides assurance that sub-recipients comply with federal grant regulations. This policy sets the criteria to establish eligibility of sub-recipients to provide annual audited financial reports and the annual OMB single audit report that identify compliance with federal laws and regulations. The reports are analyzed with emphasis on auditors assessment of sub-recipient internal controls and a standardized risk assessment is presented to management on each sub-recipient. A Management Letter is issued to each sub-recipient showing any findings on their OMB single audit report, and measurements are set for increased monitoring when an elevated level of risk is established. Management has communicated with an educated administrative staff regarding implementation of this policy. The Director of Grants and Contracts is responsible for monitoring sub-recipient adherence to financial regulations. The principal investigator is responsible for overseeing the satisfactory performance of the sub-award to ensure that goals are achieved. If there are unusual or unforeseen items, these will be investigated. Part I Line 3f The expenditures were actual expenses incurred in the region based on individual expense reports and tracking of expenditures by grant or department on the accrual basis of accounting. Part II Line 1 The expenditures were expenses incurred in the region based on award goals on the accrual basis of accounting. true Ann Robert H Lurie Childrens Hospital of Chicago 225 East Chicago Ave Box 271 Chicago IL 606112605 362170833 501c3 12948 Medical Research Baylor Research Institute BoA Lockbox 846275 1950 N Stemmons Dallas TX 75207 751921898 501c3 6337 Medical Research Brigham and Womens Hospital Bank of America NAPO Box 3887 Boston MA 022413887 042312909 501c3 167434 Medical Research Seattle Childrens Hospital PO Box 24728 Seattle WA 981240728 910564748 501c3 684157 Medical Research Univ of Minnesota Regents NW 5957PO BOX 1450 Minneapolis MN 554855957 416007513 Minnesota 14447 Medical Research University of California San Francisco UCSF Main DepositoryPO Box 748872 Los Angeles CA 900744872 946036493 501c3 6581089 Medical Research Childrens Hospital of Philadelphia PO Box 8550Lockbox 1457 Phliladelphia PA 191781457 231352166 501c3 16382 Medical Research Childrens Mercy Hospital 2401 Gillham Road Kansas City MO 64101 440605373 501c3 9473 Medical Research The Cleveland Clinic Foundation PO Box 931562 Cleveland OH 44193 340714585 501c3 100992 Medical Research Columbia University Trustees of PO Box 29789General Post Office New York NY 100879789 135598093 501c3 28515 Medical Research Dana Farber Cancer Institute Inc Attn Research AccountingMail Stop B Boston MA 02215 042263040 501c3 121292 Medical Research Duke University Box 3709Cell Biology Durham NC 27710 560532129 501c3 914192 Medical Research Dynavax Technologies Corporation 2100 Powell St Ste 900 Emeryville CA 946081844 330728374 259600 Medical Research Emory University PO Box 935084 Atlanta GA 311935084 580566256 501c3 397015 Medical Research Feinstein Institute for Medical Research 350 Community Drive Manhasset NY 11030 112673595 501c3 339969 Medical Research Fred Hutchinson Cancer Research Center 1100 Fairview Ave N J6-330PO Box 19 Seattle WA 981091024 237156071 501c3 258874 Medical Research Hospital for Special Surgery 535 East 70th Street New York NY 10021 131624135 501c3 64904 Medical Research Icahn School of Medicine at Mount Sinai One Gustave L Levy Place Box 3500Of New York NY 100296574 136171197 501c3 2330110 Medical Research Indiana University Dept 78867PO Box 78000 Detroit MI 482780867 356001673 501c3 119451 Medical Research Johns Hopkins University Central Lockbox co B of A12529 Coll Chicago IL 60693 520595110 501c3 649276 Medical Research Jonathan Corren MD Inc 10780 Santa Monica Blvd 280Allergy Los Angeles CA 90025 462346264 501c3 12417 Medical Research Joslin Diabetes Center ATTN Fiscal ServicesOne Joslin Plac Boston MA 022155306 042203836 501c3 53798 Medical Research Massachusetts General Hospital 55 Fruit StreetResearch Management Boston MA 02114 042697983 501c3 5092917 Medical Research Mayo Clinic Jacksonville 4500 San Pablo Road Jacksonville FL 32224 593337028 501c3 30000 Medical Research Medical College of Wisconsin Accounts ReceivablePO Box 26509 Milwaukee WI 532260509 390806261 501c3 72537 Medical Research National Jewish Health 1400 Jackson Street M216 Denver CO 80206 742044647 501c3 200178 Medical Research Northwestern University 633 Clark Room G547ATTN ASRSP Evanston IL 60208 362167817 501c3 56243 Medical Research Ohio State University Office of Sponsored Programs1960 Ke Columbus OH 43210 316025986 501c3 34515 Medical Research Oregon Health and Science University 3181 SW Sam Jackson Park Rd Portland OR 972393011 931176109 Oregon 39040 Medical Research Polyclinic 1145 BroadwayAttn Accounts Receivab Seattle WA 98122 910369070 501c3 25505 Medical Research Providence Health & Services WA 101 W 8th Avenue Spokane WA 992042307 364640211 501c3 21945 Medical Research Rockefeller University 1230 York Ave Box 259Financial Post New York NY 100656399 131624158 501c3 74180 Medical Research Rutgers the State University of New Jersey Grant and Contract Accounting33 Kni Piscataway NJ 08854 226001086 501c3 132541 Medical Research Sanford Research 2301 E 60th St NAttn Clinical Resea Sioux Falls SD 57104 460450378 501c3 60080 Medical Research San Diego Biomedical Research Institute 10865 Road to the Cure Suite 100 San Diego CA 92121 463481092 501c3 11217 Medical Research Stanford University PO Box 44253 San Francisco CA 941444253 941156365 501c3 136357 Medical Research State University of Iowa Attn Grant Accounting Office201 S C Iowa City IA 522424034 426004813 501c3 34442 Medical Research St Jude Childrens Research Hospital Inc PO Box 1000 Dept 949 Memphis TN 381480949 620646012 501c3 63024 Medical Research University of WA Grants 12455 Collections Drive Chicago IL 606930001 916001537 Washington 782342 Medical Research Univ of Texas SW Med Ctr Grants ManagementPO Box 841765 Dallas TX 752841765 756002868 Texas 18126 Medical Research University of Colorado-Denver PO Box 910238 Denver CO 802910238 846000555 501c3 168545 Medical Research University of Pennsylvania PO Box 785541 Philadelphia PA 171785541 231352685 501c3 162965 Medical Research University of Texas Southwestern Medical Center 5323 Harry Hines Boulevard Dallas TX 75390 756002868 Texas 213752 Medical Research University of Michigan Box 223131 Pittsburgh PA 152512131 386006309 501c3 136207 Medical Research University of North Carolina at Chapel Hill PO Box 402420Bank of America Lockbo Atlanta GA 303842420 566001393 501c3 46614 Medical Research University of Washington Box 94224 Seattle WA 981246524 916001537 Washington 431777 Medical Research University of Pittsburgh ATTN XXX-XX-XXXX Ross Street Pittsburgh PA 152620001 250965591 501c3 120192 Medical Research University of Michigan Regents of the Box 223131SSC Accounts Receivable Pittsburgh PA 152512131 386006309 Michigan 36806 Medical Research University of Alabama at Birmingham 1720 2nd Ave SouthAB 990 Birmingham AL 35294 636005396 501c3 40385 Medical Research University Of Texas Health Science Center Houston 7000 Fannin St Houston TX 770305400 741761309 Texas 7507 Medical Research University of Massachusetts Worcester 55 Lake Avenue North Worcester MA 016550002 043167352 Massachusetts 39161 Medical Research University of Texas at Austin 110 Inner Campus Dr Stop K5300 Austin TX 78712 746000203 Texas 12428 Medical Research Vanderbilt University VUMC Financial ManagementDept 1236 Dallas TX 753121236 620476822 501c3 85380 Medical Research Virginia Commonwealth University Grants Contracts 800 E Leigh St 310 Richmond VA 23284 546001758 501c3 49403 Medical Research Yale University Grant and Contract Financial Admini New Haven CT 065081873 080648973 501c3 125434 Medical Research 54 1 Part I Line 2 Sub-recipient Monitoring Policy - medical research sub awards - BRI has formal policies and procedures to assure full compliance with applicable policies and laws governing federal grants. The Sub-recipient Monitoring Policy provides assurance that sub-recipients comply with federal grant regulations. This policy sets the criteria to establish eligibility of sub-recipients to provide annual audited financial reports and the annual OMB single audit report that identify compliance with federal laws and regulations. The reports are analyzed with emphasis on auditors assessment of sub-recipient internal controls and a standardized risk assessment is presented to management on each sub-recipient. A Management Letter is issued to each sub-recipient showing any findings on their OMB single audit report, and measurements are set for increased monitoring when an elevated level of risk is established. Management has communicated with an educated administrative staff regarding implementation of this policy. The Director of Grants and Contracts is responsible for monitoring sub-recipient adherence to financial regulations. The principal investigator is responsible for overseeing the satisfactory performance of the sub-award to ensure that goals are achieved. If there are unusual or unforeseen items, these will be investigated. X X true true false false false false false false false false false Michael Labosier Chief Financial Officer 200783 26000 6612 233395 Carla Greenbaum Director 231145 26000 6562 263707 Margaret McCormick PhD Executive Director Chief Operating Officer 200681 107759 25000 6600 340040 Steven Ziegler PhD Director of Academic Affairs 241678 18420 5112 265210 William Kowk PhD Research Member 251185 26000 3600 280785 Gerald Nepom MD PhD Program Director, ITN 164068 24000 3444 191512 Gary Kaplan MD Director 1050765 499150 281948 52358 33652 1917873 David Aboulafia MD Director 589367 286 1188 20042 33503 644386 Joyce Lammert MD PhD Director 265392 29758 31806 13751 18047 358754 Jane Buckner MD Ex Officio, President 356372 185750 26000 1200 569322 Daniel Campbell PhD Center Director of Discovery Science 201917 13404 5360 220681 Bolong Cao Business Development Director, Business Development 192045 26000 4474 222519 Philip Bernstein Research Member 192321 25000 972 218293 Part I Line 1a Social club dues are provided to one member of the senior leadership team who use the club memberships for business purposes. These payments are treated as non-taxable. Part I Line 3 Benaroya Research Institute at Virginia Mason BRI delegates to Virginia Mason Health Systems its parent and sole member Board Compensation and Benefits Committee, a committee composed of independent Health System Board members to whom the BRI Board has delegated the authority to approve all compensation and benefits for the executive leaders of BRI. To ensure that such benefit plans are market competitive and reasonable, the Committee receives support and advice, including appropriate market comparability data from an independent compensation consultant with expertise in the health care industry and access to relevant market data. See Schedule O for additional disclosure. Part I Line 4b The Virginia Mason Medical Center has a Supplemental Executive Retirement Plan SERP in which certain BRI Executives participate. The SERP is a 457 f nonqualified deferred compensation plan pursuant to which plan benefits are subject to a substantial risk of forfeiture, entered into in connection with certain senior executives joining the Medical Center. The plan was approved by the Boards Compensation and Benefits Committee, a committee composed of independent board members to whom the Board delegates the authority to approve compensation and benefits to the Medical Centers most senior executives. The Committee receives advice from an independent compensation consultant to ensure that compensation and benefits, including the SERP, are market competitive and reasonable. Supplemental Executive Retirement Plans such as this are customary for senior executives in the health care industry. A WA Econ Devel Fin Auth-2019 Series A 911493002 000000000 2019-02-26 25716490 See Part VI false true false B WA Econ Devel Fin Auth-2019 Series B 911493002 000000000 2019-02-26 6000000 See Part VI false true false A 1120194 25716490 25716490 true false true true B 6000000 4001429 1998571 true false true true A false false false true true 0.04250 0.04250 false false true B false false false true true 0.04250 0.04250 false false true A false true true false false false true B false true true false false false true A true B true Part I Line A Column F Purposes To currently refund WEDFA Series 2012 B bonds issued 06/01/2012, and WEDFA Series 2016 bonds issued on 06/01/2016. Part I Line B Column F Purposes To fund research facility improvements and equipment purchases on a draw-down basis over a three-year period ending in 2022. Form 990, Part III, Line 1 Benaroya Research Institute at Virginia Mason BRI is one of the few research institutes in the world devoted to finding causes and cures for autoimmune disease and other diseases of the immune system including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, lupus, inflammatory bowel disease, cancers, allergies and infectious diseases. BRI is affiliated with the Virginia Mason Health System, which provides governance oversight, and development support through the Virginia Mason Foundation. BRIs bold mission is to predict, prevent, reverse and cure diseases of the immune system to achieve our vision of a healthy immune system for everyone. BRI is led by President Jane H. Buckner, MD, and Executive Director/COO Margaret McCormick, PhD. Discoveries at BRI are accelerated by our talented researchers, collaborative culture and application of new technologies and data analytics in a quest to understand what can cause the immune system to fall out of balance and what we can do to restore it to health. To that end, scientific activities are organized into four Centers of Discovery, a model that allows for knowledge sharing and for each Center and core lab to build on discoveries from individual labs 1 Fundamental Immunology, directed by Daniel Campbell, PhD 2 Translational Immunology, directed by Karen Cerosaletti, PhD 3 Interventional Immunology, directed by Carla Greenbaum, MD and 4 Systems Immunology, directed by Peter Linsley, PhD. In 2020 we recruited and integrated three new investigators into our institute Hamid Balouri, PhD, and John Ray, PhD into the Center for Systems Immunology and Carmen Mikacenic, MD, into the Center for Translational Immunology. In the year 2020, our vision of achieving a healthy immune system for every person took on a new urgency as we pivoted our expertise and research skills to help solve the mysteries of COVID-19. With our clinical research expertise and the help of many volunteers, we served as a trial site for testing the Pfizer vaccine for COVID -19 as well as a trial site for the drug remdesivir. We were also able to complete volunteer enrollment and push forward our Sound Life Project to help us understand what constitutes a healthy immune system and what causes it to move from health to disease. Through remote work, in the labs with strict COVID safety protocols, and in partnership with personnel and patients at Virginia Mason, we kept our momentum of research making progress against everything from devastating viruses to Crohns disease to type 1 diabetes. Form 990, Part III, Line 1 continued Donor and NIH support of COVID Disease and Immune Response. For expertise in immunology research key to understanding symptoms caused by COVID-19, BRI received more than 5.8 million dollars from the National Institutes of Health NIH to fund studies involving lung tissue and COVID, immune response to the virus, and the phenomenon of cytokine storm. This funding would not have been possible without the support and confidence of our donors in giving more than 365,000 in seed money for initial research, enabling us to obtain larger government grants. Discoveries from BRI helped identify a new cellular protection pathway that targets a vulnerability common to several different pandemic viruses. Principal investigator Adam Lacy-Hulbert, PhD, was lead author on a study showing that this pathway can protect cells from infection by Ebola virus and coronaviruses, such as SARS-CoV-2. Published in Science, the findings provided a better understanding of cellular mechanisms involved in viral resistance to inform future treatments and therapies for infectious diseases. The research illuminated a completely new role for the two genes identified and a unique approach to inhibiting virus fusion and entry into human cells - bringing us one step closer to the next generation of antiviral therapies. A team collaboration with the University of Washington yielded evidence that mild cases of COVID-19 may trigger long-term immunity from the virus. The researchers, including Dan Campbell, PhD and Jessica Hamerman, PhD, performed an analysis of SARS-CoV-2 specific immune responses at one and three months following the onset of symptoms in patients who had recovered from mild COVID-19. Most of the participants developed antibodies, B and T cells that remained present for at least three months it appeared the recovered patients had formed virus-specific memory cells showing signs of antiviral immunity. Form 990, Part III, Line 4 One unique quality of BRI is the close integration of three types of medical research - laboratory research, translational research, and clinical research - to improve lives. Our scientists collaborate to explore basic science as well as clinical applications, which is the best way to design studies with the highest potential for success. At BRI, discovery starts in the laboratory but is driven by patient issues addressed in the clinic. Form 990, Part III, Line 4a 2020 advancements of the Immune Tolerance Network are highlighted as follows Funding for the Immune Tolerance Network ITN was awarded to BRIs Dr. Jerry Nepom in 2014 from the National Institute of Allergy and Infectious Disease NIAID of the National Institutes of Health NIH. The 7-year award, totaling 27 million annually support the ITN, a research consortium established in 1999 with a primary focus on the development of new tolerogenic approaches for the treatment and prevention of disease in three clinical areas asthma and allergic diseases autoimmune diseases and immune-mediated rejection of transplanted solid organs, tissues and cells. As the Prime recipient of this grant, BRI is responsible for the management of the overall grant from NIAID including oversight of all aspects of the Networks infrastructure. The major activities in 2020 were diverse, but continued to center on preserving the ITNs cohesive project focused environment and its framework which has proven so successful in the management of a large cooperative agreement grant. Key outcomes in 2020 include the following 1 Grant Renewal The ITN was notified in late 2020 that the ITN grant renewal had been awarded to Dr. Jerry Nepom at the Benaroya ReZsearch Institute. This is a 7-year, 189M award starting in 2021. 2 Cross Network Integration The COVID 19 pandemic in 2020 presented a temporary shift in ITN priorities as personnel spread across the ITNs three main operational sites moved to a work from home WFH model. This shift was largely seamless due to past focus on careful planning and emphasis on collaboration across the ITNs major centers, located in Seattle, San Francisco and Bethesda. No changes to existing network integration were needed as the current model continued to successfully support the overall ITN program. Establishing new relationships and vital connections within the research community continued to be an ITN goal. 3 Operations and Clinical Trial Support The ITN program team at BRI issued 211 sub-awards in 2020 in support of 22 active ITN clinical trials and numerous supporting ITN mechanistic trials. 4 Supplemental Funding / Partnerships ITN central administration continued to focus on identifying additional opportunities for supplemental funding and/or funding partnerships. In 2020, the ITN received supplemental funding as the contracting component for several NIAID sponsored COVID-19 clinical trials. a Supplemental Funding Opportunities The ITN Program Team at BRI submitted four supplemental funding requests in 2020. these requests were awarded, bringing in an additional 5.9M in funding to the ITN BRI. b Partnerships. The ITN continued its relationship with two pharmaceutical partners for partial funding on two ongoing ITN studies. NIAID is the clinical sponsor on both of these trials. 5 Publication Activity In 2020, 31 ITN publications were published in prestigious research journals and were presented at domestic and international research conferences. These publications represented ITN research in all therapeutic focus areas of the ITN Type 1 Diabetes, Transplant, Autoimmune disease and Allergy and Asthma. Form 990, Part III, Line 4a continued BRIs advances in Interventional Immunology research are highlighted as follows 1 Testing a vaccine for COVID-19. BRI served as one of about 150 Pfizer COVID-19 vaccine testing sites across six countries and 39 states. First, researchers opened enrollment for the trial and spread the word that they were looking for volunteers to participate in the study. Some participants received the vaccine, and others received a placebo. Frontline workers, several Virginia Mason ER doctors, and physicians from other local hospitals were among the volunteers. Led by Carla Greenbaum, MD, the research team had only three weeks to give the first vaccine dose to more than 80 participants - while social distancing meant they could have only a few people at a time in the Clinical Research Center. To make it happen, the team mapped out detailed schedules and worked nights and weekends. At the end of each day, they entered data about potential COVID-19 illnesses and vaccine side effects, which were monitored closely by Pfizer. When enough data had been collected worldwide, Pfizer announced its safety and efficacy endpoints had been met, and the FDA independently reviewed the data to decide whether to authorize the vaccine for emergency use. In late 2020, the research team finally got word from Pfizer that the FDA had approved the vaccine for use during the pandemic emergency. 2 A Strategy to Prevent Celiac Disease in Children. A study involving BRI scientists found that introducing high doses of gluten into infants diets could prevent them from developing celiac disease. Results from the Enquiring About Tolerance EAT study, published in JAMA Pediatrics, suggest this discovery could prove an effective prevention strategy for the disease. The EAT study investigated effects of gluten - in the form of wheat-based cereal - along with breastfeeding from the age of four months. Researchers compared the results with those from infants who avoided allergenic foods and consumed only breast milk until the age of six months. The results showed that among babies who delayed gluten introduction, celiac disease at three years of age developed at higher rates than expected. In contrast, there were no cases of the disease among children who had received gluten from four months of age. Celiac disease is an autoimmune disease in which eating gluten causes the bodys immune system to attack its own tissues, causing a range of potentially severe symptoms in the gut and elsewhere. 3 Type One Diabetes Research. BRI is dedicated to seeking ways to eliminate type 1 diabetes by finding ways to predict the disease before clinical symptoms occur and to identify therapies that prevent, reverse and intervene in the disease at any stage. BRI is an international leader in type 1 diabetes research and has investigated it for more than 30 years, starting with identification of a genetic marker for the disease. Form 990, Part III, Line 4a continued Advancements in 2020 included the following 1 BRI supports Type 1 Diabetes TrialNet, a National Institutes of Health-funded clinical trial network for type 1 diabetes prevention and early treatment, serving as the TrialNet hub of 18 clinical centers worldwide working with more than 150 screening and clinical research sites. 2 Immunotherapy Can Delay T1D - Carla Greenbaum, MD, chair of TrialNet, furthered findings that immunotherapy can delay a type 1 diabetes diagnosis in people at high risk. Findings from TrialNets Teplizumab anti-CD3 Prevention Study drawing from multiple sites showed the drug that targets the immune system can delay type 1 diabetes a median of two years in children and adults at high risk. Samples collected in the original trial were then studied to help Dr. Greenbaum and others understand why some people respond to the drug better than others - and how its benefits may be extended. Dr. Greenbaum, who in 2020 directed BRIs Diabetes Research Program and served as principal investigator for its TrialNet clinical site, noted the findings and additional insights represent great news for millions with T1D, as well as relatives who are at a high risk for the disease. 3 The TrialNet Pathway to Prevention study screens relatives of people with type 1 diabetes to find out if these family members are at risk for developing diabetes. Relatives of people with type 1 diabetes are at 15 times greater risk of developing type 1 diabetes. Those who qualify have the opportunity to enroll in a prevention trial. Those with two or more autoantibodies are closely monitored for early detection of type 1 diabetes. Close monitoring of at-risk family members can reduce the chances of being diagnosed in diabetic ketoacidosis DKA, a potentially life-threatening complication. 4 As home to the JDRF Core for Clinical Assay Validation CAV, BRI plays an important role in identifying type 1 diabetes biomarkers and in helping outside researchers get the most accurate test results. The CAV is pinpointing key biomarkers, such as those indicating which patients will keep making insulin for years and which patients wont. The CAV also helps maintain quality control for a worldwide network of research labs by asking them to perform specific tests and reviewing their results. Form 990, Part III, Line 4b Translational Immunology research observations are made in the basic research lab, then quickly tested in the clinic with patients, with results brought back to the lab again in an expedient and systematic way. This type of research translates new methods to improve our ability to predict disease risk, prevent onset of disease, slow disease progression and improve safety and efficacy of treatments. At BRI, translational research addresses autoimmune and immune-mediated diseases. The BRI biorepository is a collection of blood, serum and tissue samples, as well as medical histories, from volunteers with and without diseases involving the immune system. BRI scientists and physician collaborators work together to study tissue, blood and serum samples along with the medical and demographic data. BRIs biorepository samples date back to 2000 and include multiple disease categories and a biorepository of healthy people for comparison purposes. Advancements in 2020 included the following 1 Sound Life Project - BRI completed volunteer enrollment for this study in which researchers are tracking healthy immune systems over time. Seattle-area adults in two age cohorts - 25-35 and 55-65 - are participating in this groundbreaking study to build a baseline of knowledge about the human immune system to understand disease. The goal is to lay the groundwork for better ways to diagnose, treat and prevent immune system diseases such as rheumatoid arthritis, type 1 diabetes and multiple sclerosis. Volunteers provide blood samples and health information through in-person visits and a phone app developed at BRI, allowing researchers to track their immune systems over the course of two years. The project is the initial phase of a research partnership with the Allen Institute for Immunology. BRI is providing detailed information about healthy immune systems to serve as a foundation for existing and future disease research programs. 2 Autoimmune Disease Research in the Down Syndrome Population. BRIs Bernard Khor, MD, PhD, and Virginia Mason pediatrician Rebecca Partridge, MD, continued their work leveraging a grant from the National Institutes of Health to build a Down syndrome DS biorepository to research the connection between DS and autoimmune disease. The collection includes blood, serum and tissue samples, as well as medical histories, from volunteers, people with DS and their relatives, with and without autoimmune diseases. The DS population has long been underrepresented in medical research, as nearly 50 percent of this population is living with at least one autoimmune disease. BRI is among the first to be awarded a grant dedicated to autoimmune disease in the DS population. 3 Type 1 Diabetes Fast Progressors and Prevention Strategies - Alice Long, PhD, and colleagues pursued their landmark discovery that is leading to new treatment strategies for type 1 diabetes T1D. In some people newly diagnosed with the disease, it progresses so quickly that their pancreas stops making insulin within a year. For others, the process is slower and this can make the disease easier to manage. The researchers discovery enables early identification of fast progressors to potentially match them with treatments to help them stay healthier for much longer. The researchers identified important differences between fast progressors and people whose disease progresses slowly. Dr. Longs team showed that slow progressors have higher levels of exhausted CD8 T cells - cells that are worn out from attacking the pancreas. The discovery could lead to a test that identifies how quickly individual patients will lose their ability to make insulin. Then, Dr. Long received additional funding to investigate why CD8 T cells become exhausted. For people with T1D, a therapy that would slow down or even stop attacker cells would prolong their ability to make insulin, which makes their lives much easier and significantly reduces their long-term health risks. Peter Linsley, PhD, led BRIs bioinformatics team in helping to analyze a vast amount of data from the cells. While researchers are typically only able to look at two or three aspects of each cell, Dr. Linsleys team used innovative technology to help Dr. Long and colleagues collect and analyze data on up to 30 aspects of each cell. 4 In 2020, BRI also received a 5.4 million contract award from the NIH to improve treatments for patients diagnosed with rheumatoid arthritis. Form 990, Part III, Line 4c 1 Fundamental Immunology The Center for Fundamental Immunology investigates the immune system to understand how it works in health and disease. At BRI, we employ a variety of methods to examine the immune system function at the genetic, molecular and cellular levels. These include developing novel model systems of autoimmune and inflammatory disease, used to determine how activities of the immune system are regulated and how regulatory mechanisms break down in autoimmunity, allergy, asthma and COVID-19. We also leverage samples from healthy subjects and patients with immune-mediated diseases to study immune system function and identify potential therapeutic targets. 2 Systems Immunology With the explosion of data from genome studies and molecular profiling technologies, huge amounts of biological information are now available. BRI scientists in this Center use complex systems theory and high throughput techniques as well as mathematical and computational tools to understand the functioning of the immune system in health and disease. Form 990, Part III, Line 4d BRI oversees the Clinical Research Program at Virginia Mason Medical Center, uniquely combining the expertise of a world-renowned medical research institute with the care of a healthcare quality leader. The Clinical Research Program supports Virginia Mason clinical investigators in studies across a wide variety of autoimmune and immune-mediated diseases and conditions, as well as a broad range of other diseases such as cancer and cardiac disease. The Clinical Research Program staff annually enrolls approximately 1500 study participants into Virginia Mason trials, but numbers were fewer in year 2020 due to the pandemic. 1 Testing a New MS Therapy - a research study at BRI and Virginia Mason is seeking to find out if an experimental oral drug, similar to a currently available MS medication, would be just as effective as the current one, but with fewer gastrointestinal side effects. In an earlier study, half the research participants took this experimental drug and half took the current drug. Participants who finished the five-week study then enrolled in a two-year study of the experimental drug. Form 990, Part VI, Section A, Line 1a The governing body delegates to an Executive Committee comprised of four officers of the Board and the Chairs of each standing Board Committee, the authority of the Board of Directors in the management of the corporation as may be deemed by the Executive Committee to be appropriate, to be exercised in time periods between regularly scheduled meetings of the Board of Directors provided that the Executive Committee has the authority to act only in time sensitive or emergency situations. The President and the Executive Director of the corporation serve as ex officio members of the Executive Committee without voting rights. The Executive Committee does not have the authority to amend, alter or repeal the bylaws elect, appoint or remove any member of such Executive Committee or any director or officer of the corporation amend the articles of incorporation adopt a plan of merger or adopt a plan of consolidation with another corporation authorize the sale, lease or exchange of all or substantially all of the property and assets of the corporation not in the ordinary course of business authorize the voluntary dissolution of the corporation or revoke proceedings therefore adopt a plan for the distribution of the assets of the corporation or amend, alter or repeal any resolution of the Board which by its terms provides that it shall not be amended, altered or repealed by such Executive Committee. The Executive Committee also serves as the planning committee for the Board of Directors and oversees any compliance issues raised by the Board of Directors. Form 990, Part VI, Section A, Line 4 Effective January 1, 2021 Franciscan Health System FHS, Virginia Mason Health System VMHS, and CommonSpirit HealthCommonSpirit, a member of FHS, completed the affiliation transaction the Affiliation contemplated by the Affiliation Agreement, dated as of December 31, 2020, pursuant to which, among other things, CommonSpirit formed Virginia Mason Franciscan Health, a Washington nonprofit corporation VMFH. After the effective date, CommonSpirit and VMHS are the sole corporate members of VMFH, which is a controlleld subsidiary of CommonSpirit and will be consolidated with CommonSpirit for accounting purposes. As a result of the Affiliation, VMFH now governs and manages the combined operations of FHS, Virginia Mason Medical Center VMMC Benaroya Research Institue BRI, and certain other affiliates of FHS and VMMC the Combined System, subject to certain VMHS protective reserved powers and other reserved powers held by CommonSpirit and VMFH is now the sole corporate member of both VMMC and BRI. Form 990, Part VI, Section A, Line 6,7 Virginia Mason Health System VMHS is the sole corporate member of Benaroya Research Institute at Virginia Mason BRI. VMHS as the sole voting member has the following approval rights a election or appointment of Directors and Officers of the Board of Directors b removal of Directors and Officers of the Board of Directors including any executive officer of the corporation c approval of all long-range and short-range plans proposed by the Board of Directors d approval of the annual capital and operating budgets proposed by the Board of Directors e approval of the borrowing of funds where the amount borrowed is in excess of Five Hundred Thousand Dollars 500,000 f approval of the sale, lease, exchange, mortgage, pledge or disposal of all or substantially all of the property and assets g approval of all amendments to or repeal of the Agreement Association or the Bylaws of the corporation h all other rights and powers as specified in the Washington Nonprofit Corporation Act. Form 990, Part VI, Section B, Line 11b The Form 990 tax return is reviewed by the BRI advisory Finance Committee and the BRI advisory Board prior to filing. The final Form 990 return is provided to each member of the advisory Board via electronic delivery. Form 990, Part VI, Section B, Line 12c The VMHS Governance Committee has been delegated accountability for oversight of the process for disclosure, evaluation and management of conflict of interest involving any member of the BRI Board of Directors, executive leadership or key employees Covered Person. Pursuant to the Conflict of Interest Policy, an annual conflict of interest questionnaire is distributed to all Covered Persons. In addition, a Covered Person has an on-going duty to disclose the existence of a conflict of interest at any time an actual or potential conflict arises. Each Covered Person is required upon appointment and annually thereafter to attest to a statement that affirms that such person has a received a copy of the Conflict of Interest Policy b has read and understands the Policy c has agreed to comply with the Policy and d understands that BRI is a charitable organization and that in order to maintain its federal tax exemption must engage in activities that accomplish its tax-exempt purposes. Written disclosures are reviewed by the Governance Committee to determine if an actual or potential conflict of interest exists and if so, how it should be managed. The Covered Person is informed in writing regarding the determination the Conflict of Interest Management Plan. No Covered Person with an actual or potential conflict of interest shall engage in an activity on BRIs behalf related to the disclosed actual or potential Conflict of Interest unless such activity is permitted by the Conflict of Interest Management Plan or until the Covered Person has undertaken all steps set forth in the Management Plan to manage, reduce or eliminate the conflict. All Covered Persons have a duty to disclose the existence of any actual or potential conflict of interest with respect to meeting agenda items. The Conflict of Interest Policy requires that copies of the Conflict of Interest Questionnaire be completed annually by each covered Person and any Conflict of Interest Management Plan be maintained. Form 990, Part VI, Section B, Line 15 The VMHS Compensation and Benefits Board Committee, a committee composed solely of independent directors none of whom have a conflict of interest, is accountable for setting reasonable total compensation packages for each executive, officer and key employee Executive consistent with BRIs compensation philosophy and principles. The Committee approves annual goals and performance criteria which are used in determining merit increases and variable compensation opportunities. The Committee assesses performance against these goals. The Committee selects and engages a qualified independent compensation consultant to review and analyze the total compensation and benefits packages of the Executives. The Committee as part of its analysis obtains from the compensation consultant appropriate comparability data including total compensation paid by similarly situated organizations for positions that are functionally comparable to each of the Executives. The Committee will consider the significant terms of the agreement with each Executive including the total compensation to be paid and the employees duties and responsibilities. Consistent with the compensation philosophy and principles, the Committee approves total compensation packages for each of the Executives based on information presented to the Committee, reasonableness and the best interest of BRI. The Committees decisions regarding compensation for each Executive are documented in written resolutions and minutes of the Committee. The Committee promptly reports its actions to the VMHS board which reports are reflected in the Boards minutes. The individual positions who were reviewed in 2020 were Jane Buckner, BRI President and Director, Carla Greenbaum, BRI Director, Steven Ziegler, Director, Academic Affairs, Michael Labosier, Chief Financial Officer, and Margaret McCormick, Executive Director and Chief Operating Officer. Form 990, Part VI, Section C, Line 19 The organizations Articles, Bylaws, Conflict of Interest Policy and financial statements are made available upon request. Virginia Mason Health System 1100 Ninth Avenue Seattle WA 98101 911351110 Fundraising WA Sec 501c3 7 N/A false Virginia Mason Medical Center 1100 Ninth Avenue Seattle WA 98101 910565539 Health Care WA Sec 501c3 3 VMHS false Virginia Mason Institute 1100 Ninth Avenue Seattle WA 98101 263763656 Education WA Sec 501c3 9 VMMC false Yakima Valley Memorial Hospital Association 2811 Tieton Drive Yakima WA 98902 910567263 Health Care WA Sec 501c3 3 VMHS false false false true false false false false false false true true false false true false true true false false Benaroya Research Institute at Virginia Mason 1200 Ninth Avenue Seattle WA 98101 910653422 0 0 0 71349522 71349522 57878 14470 0 0 0 Virginia Mason Medical Center 1100 Ninth Avenue Seattle WA 98101 910565539 X 129023 80424 209447 1140696406 1140905853 925495 231373 0 0 0 Virginia Mason Institute 1100 Ninth Avenue Seattle WA 98101 263763656 0 0 0 3869715 3869715 3139 785 0 0 0 Virginia Mason Health System 1100 Ninth Avenue Seattle WA 98101 911351110 0 0 0 16626427 16626427 13487 3372 0 0 0